Prevention of HEMOrhagic Risk in Upper MYOmeCTomy by Use of Misoprostol.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-12

Study Completion Date

2028-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In France, uterine fibroids or leiomyomas are the most common benign tumour in women of childbearing age.

In 30% of cases, fibroids are symptomatic (menorrhagia, anaemia, pain), in which case surgical management is indicated. This is known as myomectomy, and can be performed by hysteroscopy, laparoscopy (laparoscopy) or laparotomy, depending on the number, size and position of the fibroids.

Intraoperative bleeding is the main surgical difficulty. For this reason, a number of studies have focused on ways of minimizing the risk of bleeding.

A good surgical indication, prevention of anaemia (iron deficiency) and transient occlusion of the uterine arteries during surgery help to reduce this risk. There are also drugs available to reduce intraoperative bleeding, but few studies have been carried out to assess their real effectiveness. One such product is Misoprostol, commonly used in gynecology. Its muscle-contracting properties suggest that it could have a beneficial effect on bleeding during surgery. What's more, this treatment has been used for many years and is reputed to be very well tolerated. The most frequent side effects are digestive, with a risk of abdominal pain in the form of cramps, nausea or vomiting.

The investigators therefore decided to set up the HEMOMYOC study to demonstrate a significant reduction in bleeding during laparotomy or laparoscopic myomectomy after taking oral misoprostol in combination with transient occlusion of the uterine arteries, compared with placebo. It would seem that the ease of use and good tolerance of misoprostol, in combination with transient occlusion of the uterine arteries, could be of real benefit in preventing intraoperative morbidity in myomectomies, whatever the surgical approach. To date, no studies have been carried out in this area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids

NCT05078307

Uterine Fibroids

UNKNOWN NA

Evaluation of a Hysteroscopic Morcellator in Hysteroscopic Treatment of Submucosal Fibroids

NCT02406898

Evaluate Both Technics on Procedure Duration Characteristics and Perioperative Complications

UNKNOWN NA

Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy

NCT06325501

Myoma;Uterus

RECRUITING PHASE3

Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy

NCT02288130

Fibroids

UNKNOWN PHASE4

Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.

NCT04694677

Myoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myoma;Uterus Myomectomy; Surgical Blood Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment arm with misoprostol

Group Type EXPERIMENTAL

myomectomy with misoprostol

Intervention Type PROCEDURE

myomectomiy after administration of misoprostol 400μg PO (experimental group)

Placebo arm

Group Type PLACEBO_COMPARATOR

myomectomy with placebo

Intervention Type PROCEDURE

myomectomy after administration of placebo (control group)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

myomectomy with placebo

myomectomy after administration of placebo (control group)

Intervention Type PROCEDURE

myomectomy with misoprostol

myomectomiy after administration of misoprostol 400μg PO (experimental group)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 to 43
* Symptomatic myomas (bleeding, pain or infertility)
* Indication for laparoscopic myomectomy Fibroma ≤ 10cm or number ≤ to 4 fibroids
* Indication for myomectomy by laparotomy Fibroma \> 10cm, Number \> to 4 fibroids
* OTAU possible intraoperatively (Clip on uterine artery and tourniquet placement)
* Speak and understand French
* Affiliated with a social security scheme.

Exclusion Criteria

* History of major uterine surgery or myomectomy (excluding hysteroscopic myomectomy)
* Allergy to misoprostol and lactose
* Patients with hypersensitivity to misoprostol and/or other prostaglandins or to any of the product's excipients.
* Patients taking aspirin or anti-coagulants
* Patients with haemostasis disorders
* Malnourished patients
* Patients with hepatic or renal insufficiency
* Pregnancy, suspected ectopic pregnancy and breast-feeding women.
* Minors
* Guardianship, curatorship, deprived of liberty, safeguard of justice

Minimum Eligible Age

18 Years

Maximum Eligible Age

43 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No